Working with International Collaborators Mary

Working with International Collaborators Mary
1 / 1
Working with International Collaborators Mary - slide 1 of 35 Working with International Collaborators Mary - slide 2 of 35 Working with International Collaborators Mary - slide 3 of 35 Working with International Collaborators Mary - slide 4 of 35 Working with International Collaborators Mary - slide 5 of 35 Working with International Collaborators Mary - slide 6 of 35 Working with International Collaborators Mary - slide 7 of 35 Working with International Collaborators Mary - slide 8 of 35 Working with International Collaborators Mary - slide 9 of 35 Working with International Collaborators Mary - slide 10 of 35 Working with International Collaborators Mary - slide 11 of 35 Working with International Collaborators Mary - slide 12 of 35 Working with International Collaborators Mary - slide 13 of 35 Working with International Collaborators Mary - slide 14 of 35 Working with International Collaborators Mary - slide 15 of 35 Working with International Collaborators Mary - slide 16 of 35 Working with International Collaborators Mary - slide 17 of 35 Working with International Collaborators Mary - slide 18 of 35 Working with International Collaborators Mary - slide 19 of 35 Working with International Collaborators Mary - slide 20 of 35 Working with International Collaborators Mary - slide 21 of 35 Working with International Collaborators Mary - slide 22 of 35 Working with International Collaborators Mary - slide 23 of 35 Working with International Collaborators Mary - slide 24 of 35 Working with International Collaborators Mary - slide 25 of 35 Working with International Collaborators Mary - slide 26 of 35 Working with International Collaborators Mary - slide 27 of 35 Working with International Collaborators Mary - slide 28 of 35 Working with International Collaborators Mary - slide 29 of 35 Working with International Collaborators Mary - slide 30 of 35 Working with International Collaborators Mary - slide 31 of 35 Working with International Collaborators Mary - slide 32 of 35 Working with International Collaborators Mary - slide 33 of 35 Working with International Collaborators Mary - slide 34 of 35 Working with International Collaborators Mary - slide 35 of 35
Working with International Collaborators Mary Kirker Chief, Grants Management Officer National Institute of Allergy and Infectious Diseases, National Institutes of Health 2016 NIH Regional Seminar International Collaboration HHS Secretary

Related Topics

Download this presentation From Below

"Working with International Collaborators Mary" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Presentation Transcript

01
Working with International Collaborators Mary Kirker
Chief, Grants Management Officer
National Institute of Allergy and Infectious Diseases, National Institutes of Health

2016 NIH Regional Seminar<br>
02
International Collaboration HHS Secretary says US plays key role in global health
(January 2015)

The U.S. has a "very strong" role to play in global health, not least in the battle to control Ebola and other threats to the domestic as well as worldwide populations, according to Sylvia Burwell, Secretary of the U.S. DHHS, which oversees the NIH.

"The role of HHS in the global health
space is going to be front and center,"
Burwell said during a recent visit to
NIH to tour the main campus
and meet staff.
Health and Human Services Secretary Sylvia Burwell visited NIH recently for her first town hall meeting with staff. She was greeted by (from right) NIH Director Dr. Francis Collins, National Cancer Institute Director Dr. Harold Varmus and NIH Deputy Director Dr. Lawrence Tabak.<br>
03
International Collaboration Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial….NIH News - March 26, 2015

Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review.

“We are grateful to the Liberian people who
volunteered for this important clinical trial
and encouraged by the study results seen
with the two investigational Ebola
vaccine candidates,” said NIAID Director Anthony S. Fauci, M.D.<br>